Selecta Biosciences Announces Appointment of Kevin Tan as Chief Financial Officer
Selecta Biosciences, Inc. (NASDAQ: SELB) announced the appointment of Kevin Tan as Chief Financial Officer. Tan, with extensive experience in gene therapy and rare diseases, is expected to enhance Selecta’s financial strategies. The company anticipates significant milestones, including an IND filing for methylmalonic acidemia and data on an empty capsid study later this year. Selecta leverages its ImmTOR™ platform to develop therapies that mitigate unwanted immune responses, aiming to improve treatment options for patients with autoimmune diseases and genetic disorders.
- Kevin Tan appointed as CFO, bringing expertise in financing and gene therapy.
- Anticipated IND filing for methylmalonic acidemia in Q3 2021.
- Upcoming readout from empty capsid study in Q4 2021.
- None.
WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of Kevin Tan as chief financial officer.
“Kevin’s deep financial expertise and experience in the gene therapy and rare disease landscape makes him an ideal fit for Selecta’s executive team,” said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. “This is an exciting time for Selecta on the heels of our recent collaboration with Cyrus Biotechnology to unlock a new generation of innovative biologic therapeutics and our anticipated milestones in gene therapy, including an IND filing for methylmalonic acidemia in Q3 and a readout from our empty capsid study in Q4 2021. We are thrilled to welcome Kevin to the team as we seek to deliver our unique ImmTOR platform to patients living with debilitating diseases, and we are confident that his impressive track record in capital management and financings, in both the biotech and investment sectors, will be invaluable as we continue to pursue new partnership opportunities and advance multiple assets through the clinic.”
Mr. Tan added, “I am excited to join Selecta at this critical juncture in the company’s growth. I look forward to working with the entire Selecta team to deliver on our shared commitment to patients in need of more therapeutic options and to drive long-term value for shareholders.”
Prior to joining Selecta, Mr. Tan served as treasurer at Sarepta Therapeutics where he was responsible for the liquidity and capital management of the company. At Sarepta, he led numerous financings across equity and debt markets and was a key member of the Business Development team. Prior to his time at Sarepta, Mr. Tan served as Senior Portfolio Manager at CPP Investments, a Canadian pension fund where he managed billions in capital across the public markets.
Mr. Tan holds a Bachelor of Commerce from Queen’s University at Kingston, a Masters of Engineering in Operations Research & Financial Engineering from Princeton University and a Masters of Business Administration from The University of Chicago Booth School of Business.
About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.
Selecta Forward-Looking Statements
Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the Company”), including without limitation, statements regarding the unique proprietary technology platform of the Company, and the unique proprietary platform of its partners, the programs and disease indication targets anticipated under this collaboration, the potential of our partners to develop or redesign any protein therapeutics, the ability of any drug candidate developed under the collaboration to offer a therapeutic benefit, including the promotion of expansion of regulatory T cells for the treatment of autoimmune disease indications, the potential of ImmTOR to enable re-dosing of AAV gene therapy and to mitigate immunogenicity, the potential of ImmTOR and the Company’s product pipeline to treat chronic refractory gout, IgA nephropathy, PBC, MMA or OTC, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, the Company’s ability to conduct those clinical trials and studies, the potential of any therapies developed by the Company to fulfill unmet medical needs, the potential of the ImmTOR technology platform generally and the Company’s ability to grow its strategic partnerships, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including the uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, the unproven approach of the Company’s ImmTOR technology, our partners’ ability to re-engineer or develop any protein therapeutics, potential delays in enrollment of patients, undesirable side effects of the Company’s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the Company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company’s recurring losses from operations and negative cash flows from operations raise substantial doubt regarding its ability to continue as a going concern, substantial fluctuation in the price of its common stock, and other important factors discussed in the “Risk Factors” section of the Company’s most recent Quarterly Report on Form 10-Q to be filed after this release, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release.
For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com
For Media:
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com
FAQ
Who is the new Chief Financial Officer of Selecta Biosciences?
What experience does Kevin Tan bring to Selecta Biosciences?
What are the expected milestones for Selecta Biosciences in 2021?
